Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of …

H Tsutsui, NM Albert, AJS Coats, SD Anker… - Journal of Cardiac …, 2023 - Elsevier
Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of …

Recent advances in the pharmacological therapy of chronic heart failure: evidence and guidelines

H Tsutsui - Pharmacology & Therapeutics, 2022 - Elsevier
Heart failure (HF) is a clinical syndrome with symptoms and or signs caused by a structural
and/or functional cardiac abnormality and associated with elevated natriuretic peptide levels …

Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure

RJ Mentz, JH Ward, AF Hernandez, S Lepage… - Journal of the American …, 2023 - jacc.org
Background US guidelines recommend consideration of sacubitril/valsartan in chronic heart
failure (HF) and mildly reduced or preserved ejection fraction (EF). Whether initiation is safe …

[HTML][HTML] Pericyte detachment and renal congestion involve interstitial injury and fibrosis in Dahl salt-sensitive rats and humans with heart failure

H Ito, T Hirose, S Sato, C Takahashi, R Ishikawa… - Hypertension …, 2023 - nature.com
Congestive heart failure produces fluid volume overload, central and renal venous pressure
elevation, and consequently renal congestion, which results in worsening renal function …

Epidemiology, pathophysiology, diagnosis, and therapy of heart failure with preserved ejection fraction in Japan

M Obokata, H Sorimachi, T Harada, K Kagami… - Journal of Cardiac …, 2023 - Elsevier
Heart failure (HF) with preserved ejection fraction (HFpEF) is a global health care problem,
with diagnostic difficulty, limited treatment options and high morbidity and mortality rates …

[HTML][HTML] Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction …

Y Sugita, K Ito, Y Yoshioka, S Sakai - Cardiovascular Diabetology, 2023 - Springer
Background Type 2 diabetes mellitus (T2DM) is a frequently observed complication in
patients with heart failure with preserved ejection fraction (HFpEF). Although a characteristic …

[HTML][HTML] Prognosis and diastolic dysfunction predictors in patients with heart failure and recovered ejection fraction

T Takada, K Matsuura, Y Minami, T Abe, A Yoshida… - Scientific Reports, 2022 - nature.com
There is limited data on whether diastolic dysfunction in patients with heart failure (HF) and
recovered ejection fraction (HFrecEF) is associated with worse prognosis. We …

The concept of aggressive nutrition therapy and clinical indication: A position paper

S Nishioka, S Nakahara, M Takasaki, N Shiohama… - Clinical Nutrition …, 2022 - Elsevier
Aggressive nutrition therapy is a nutritional management method that sets energy intake
requirements by adding the amount of energy accumulated to energy consumption. It is …

[HTML][HTML] Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome

H Akiyama, A Nishimura, N Morita… - Frontiers in …, 2023 - frontiersin.org
Cardio-renal-metabolic (CRM) syndrome, which involves type 2 diabetes mellitus (T2DM),
chronic kidney disease (CKD), and heart failure (HF), is a serious healthcare issue globally …

[HTML][HTML] Nutritional management of heart failure

K Kida, I Miyajima, N Suzuki, BH Greenberg… - Journal of …, 2023 - Elsevier
Nutrition in the cardiovascular field to date has focused on improving lifestyle-related
diseases such as hypertension and diabetes from the viewpoint of secondary prevention …